TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3100877

Group type: EXPERIMENTAL
Intervention: Beclomethasone nasal solution
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Flunisolide
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cromolyn
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Glucocorticoids (Beclomethasone and Flunisolide)
Number of subjects: 120
Study: 30636826

Group type: EXPERIMENTAL
Intervention: 6 mg melatonin tablets 45 min before sleep for 3 days after surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 26910256

Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 581

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 581
Study: 24854816

Group type: EXPERIMENTAL
Intervention: Advertent exposure to media body ideal images
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Inadvertent exposure to media body ideal images
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control images
Number of subjects: 174
Study: 22697189

Group type: EXPERIMENTAL
Intervention: Aripiprazole-IM-depot (400 mg every 4 weeks, with coadministration of oral aripiprazole for the first 2 weeks)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 403
Study: 20840173

Group type: EXPERIMENTAL
Intervention: Individual counseling
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 403

Group type: COMPARATOR
Intervention: Placebo pill
Number of subjects: 403
Study: 17324600

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) 0.058 IU/kg/day for 6 days
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 16246996

Group type: COMPARATOR
Intervention: Bupropion SR (150 mg twice daily)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Nortriptyline (75 mg once daily)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Bupropion SR
Number of subjects: 255

Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Control (placebo)
Number of subjects: 255
Study: 11893367

Group type: EXPERIMENTAL
Intervention: Antiresorptive drugs (e.g., alendronate)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alendronate (in the Fracture Intervention Trial)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Antiresorptive treatments (general)
Number of subjects: 12
Study: 8154632

Group type: EXPERIMENTAL
Intervention: Albuterol via metered dose inhaler (MDI)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Albuterol via AeroChamber
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Albuterol via OptiHaler
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo via metered dose inhaler (MDI)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo via AeroChamber
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo via OptiHaler
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: All devices (MDI, AeroChamber, OptiHaler)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: MDI
Number of subjects: 18
Study: 3341973

Group type: EXPERIMENTAL
Intervention: 500 mW laser power directed at anterior trabecular meshwork
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: 800 mW laser power directed at posterior trabecular meshwork
Number of subjects: 119

Group type: COMPARATOR
Intervention: ALT procedure
Number of subjects: 119
Study: 31975494

Group type: EXPERIMENTAL
Intervention: Biventricular (BiV) pacing
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham pacing
Number of subjects: 31
Study: 31564432

Group type: EXPERIMENTAL
Intervention: ultra‐rapid whole‐genome sequencing (urWGS)
Number of subjects: 213

Group type: COMPARATOR
Intervention: rapid whole‐exome sequencing (rWES)
Number of subjects: 213

Group type: COMPARATOR
Intervention: rapid whole‐genome sequencing (rWGS)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: reflexing to trio after negative proband analysis
Number of subjects: 213
Study: 28152016

Group type: EXPERIMENTAL
Intervention: Exposure to digital marketing contents of energy drinks (via websites and social media for 8 minutes)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no exposure to digital marketing)
Number of subjects: 60
Study: 25119144

Group type: EXPERIMENTAL
Intervention: Full-color graphic warning labels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Black-and-white graphic warning labels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Warning text (no graphic image)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgeon General's warning labels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No warning
Number of subjects: 0
Study: 24063778

Group type: EXPERIMENTAL
Intervention: Three-site abdominal hot-stone stimulation (umbilicus, superior-umbilicus, inferior-umbilicus) for 9 min
Number of subjects: 25

Group type: COMPARATOR
Intervention: One-site abdominal hot-stone stimulation (umbilicus) for 9 min
Number of subjects: 25
Study: 22256669

Group type: EXPERIMENTAL
Intervention: Vertical/horizontal combination grab bar configuration
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: L-shaped bar configuration
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Vertical/angled combination grab bar configuration
Number of subjects: 80

Group type: COMPARATOR
Intervention: No bars (control group)
Number of subjects: 80
Study: 19636001

Group type: EXPERIMENTAL
Intervention: irinotecan/fluorouracil, fluorouracil/oxaliplatin, or irinotecan/oxaliplatin
Number of subjects: 1412
Study: 16451762

Group type: EXPERIMENTAL
Intervention: Padding in dental mirror handle design
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Interaction of diameter and weight in dental mirror handle design
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Weight in dental mirror handle design
Number of subjects: 19
Study: 15247140

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 136
Study: 11377155

Group type: EXPERIMENTAL
Intervention: Bullard laryngoscope (BL)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Flexible fiberoptic bronchoscope (FFB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: FFB with no cricoid pressure
Number of subjects: 50
Study: 9225183

Group type: EXPERIMENTAL
Intervention: Laryngotracheoplasty
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study: 8495830

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Endoscopic injection sclerotherapy
Number of subjects: 50
Study: 2468875

Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg once daily
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg once daily
Number of subjects: 22
Study: 31138156

Group type: EXPERIMENTAL
Intervention: Transplant hospitals
Number of subjects: 7803

Group type: COMPARATOR
Intervention: Non-transplant hospitals
Number of subjects: 7803

Group type: EXPERIMENTAL
Intervention: Transplant and non-transplant hospitals
Number of subjects: 7803
Study: 28665542

Group type: EXPERIMENTAL
Intervention: Stepped care (N=570)
Number of subjects: 1012

Group type: COMPARATOR
Intervention: Standard care (N=442)
Number of subjects: 1012

Group type: EXPERIMENTAL
Intervention: Stepped care (N=341)
Number of subjects: 1012

Group type: COMPARATOR
Intervention: Standard care (N=234)
Number of subjects: 1012
Study: 25512220

Group type: EXPERIMENTAL
Intervention: Enlite continuous glucose monitoring sensor system
Number of subjects: 0
Study: 24305424

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A and hyaluronic acid filler
Number of subjects: 20

Group type: COMPARATOR
Intervention: Botulinum toxin A alone
Number of subjects: 20
Study: 21429720

Group type: EXPERIMENTAL
Intervention: 15-g soy protein and 100-mg isoflavone
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 15-g milk protein and 100-mg isoflavone
Number of subjects: 180

Group type: COMPARATOR
Intervention: 15-g milk protein (placebo group)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Soy group
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Iso group
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 180
Study: 18462730

Group type: EXPERIMENTAL
Intervention: Myo-inositol combined with folic acid (Inofolic) 2 g twice a day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Folic acid alone
Number of subjects: 60
Study: 17552953

Group type: EXPERIMENTAL
Intervention: 1-day ciprofloxacin XR 1000 mg
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: 3-day ciprofloxacin XR 1000 mg
Number of subjects: 497
Study: 15578804

Group type: EXPERIMENTAL
Intervention: Hydrochloric acid aerosol pH 5.0
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Hydrochloric acid aerosol pH 3.0
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Hydrochloric acid aerosol pH 2.0
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Hydrochloric acid aerosol (all pH levels)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Propranolol pretreatment
Number of subjects: 79
Study: 11738848

Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study: 10193275

Group type: EXPERIMENTAL
Intervention: Air tonometry (raPCO2)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Saline tonometry (rsPCO2)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Comparison of air and saline tonometry
Number of subjects: 19
Study: 7835330

Group type: EXPERIMENTAL
Intervention: FE-27 (27 mg iron x day‐1)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: FE-9 (9 mg iron x day‐1)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both FE-9 and FE-27
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 3284974

Group type: EXPERIMENTAL
Intervention: Melphalan and Prednisone (MP)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Semustine, Cyclophosphamide, and Prednisone (MeCP)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Melphalan, Prednisone, Cyclophosphamide, Semustine, and Vincristine (MPCCV)
Number of subjects: 410
Study: 31841023

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for 8 weeks
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) for 8 weeks
Number of subjects: 130

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT) and Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 130
Study: 28541646

Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Geriatric case management (CM)
Number of subjects: 58
Study: 28254462

Group type: EXPERIMENTAL
Intervention: ASP3652 25 mg twice daily
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: ASP3652 300 mg twice daily
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: ASP3652 75 mg, 150 mg, or 300 mg once daily
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: ASP3652 (all doses)
Number of subjects: 239
Study: 26457036

Group type: EXPERIMENTAL
Intervention: High myopes
Number of subjects: 104

Group type: COMPARATOR
Intervention: Other refractive groups (hyperopes, emmetropes, lower myopes)
Number of subjects: 104
Study: 23480601

Group type: EXPERIMENTAL
Intervention: Retained presumed intraocular cotton fibers
Number of subjects: 14

Group type: COMPARATOR
Intervention: No postoperative intraocular cotton fibers (Control)
Number of subjects: 14
Study: 21547897

Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (CYC) treatment for 12 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subgroup of patients with 50% or more lung zone involvement by reticular infiltrates and MRSS of at least 23
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with less severe HRCT findings and lower MRSS at baseline
Number of subjects: 0
Study: 18001798

Group type: EXPERIMENTAL
Intervention: Intravesical pentosan polysulfate sodium plus oral pentosan polysulfate sodium
Number of subjects: 41

Group type: COMPARATOR
Intervention: Intravesical placebo plus oral pentosan polysulfate sodium
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study: 16818861

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 25
Study: 14602435

Group type: EXPERIMENTAL
Intervention: Parent-initiated oral prednisolone (20 mg once daily for 5 days)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 10759619

Group type: EXPERIMENTAL
Intervention: roxithromycin with omeprazole
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: roxithromycin with lansoprazole
Number of subjects: 12
Study: 8821390

Group type: EXPERIMENTAL
Intervention: M+S condition (voluntary movements of the right index finger triggering electrical stimulus)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Task SEFs (during electrical stimulation of the right index finger)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control SEFs (recorded at the beginning of the experiment during rest)
Number of subjects: 5
Study: 1434725

Group type: EXPERIMENTAL
Intervention: Desmopressin (0.3 micrograms/kg)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 4020257

Group type: EXPERIMENTAL
Intervention: Lidocaine infusion
Number of subjects: 5
Study: 30825795

Group type: EXPERIMENTAL
Intervention: Nicotine Gum
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Aided Quit Attempts
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Unaided Quit Attempts
Number of subjects: 517
Study: 29274660

Group type: EXPERIMENTAL
Intervention: Self-Awareness
Number of subjects: 135

Group type: COMPARATOR
Intervention: Promise
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control
Number of subjects: 135
Study: 27055257

Group type: EXPERIMENTAL
Intervention: Medical device (MD; a capsule whose main component is a cross‐linked protein)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg/day and 1 capsule/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 0
Study: 24665980

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 750 mg/d
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (Transmetil 1000 mg/d or Essentiale 1368 mg/d)
Number of subjects: 30
Study: 22462425

Group type: EXPERIMENTAL
Intervention: Diclofenac (75 mg twice daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Naproxen (500 mg twice daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both diclofenac and naproxen
Number of subjects: 40
Study: 20401617

Group type: EXPERIMENTAL
Intervention: 5-week elimination diet
Number of subjects: 27

Group type: COMPARATOR
Intervention: Normal diet (control group)
Number of subjects: 27
Study: 17519049

Group type: EXPERIMENTAL
Intervention: lornoxicam 16 mg
Number of subjects: 57

Group type: COMPARATOR
Intervention: tenoxicam 40 mg
Number of subjects: 57
Study: 15226623

Group type: EXPERIMENTAL
Intervention: Ticlopidine (200 mg/day) plus aspirin (81 mg/day)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Cilostazol (200 mg/day) plus aspirin (81 mg/day)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Cilostazol (200 mg/day)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Ticlopidine (200 mg/day)
Number of subjects: 282
Study: 11285053

Group type: EXPERIMENTAL
Intervention: Total sleep deprivation (TSD)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: SWS interruption
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: REM sleep interruption
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Recovery sleep after SWS interruption
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Recovery sleep after REM sleep interruption
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Thermal pain thresholds
Number of subjects: 9
Study: 9824569

Group type: EXPERIMENTAL
Intervention: Omeprazole 10 mg daily
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 7925336

Group type: EXPERIMENTAL
Intervention: Pethidine 1 mg kg‐1 and atropine 0.02 mg kg‐1 intramuscularly 90 min prior to surgery (n = 10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Midazolam 0.5 mg kg‐1 and atropine 0.02 mg kg‐1 orally, 120 min before surgery (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both regimens (Pethidine and Midazolam)
Number of subjects: 20
Study: 2697552

Group type: EXPERIMENTAL
Intervention: Lactitol (19 g anhydrous)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Lactulose (19 g)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Other test compounds (Sorbitol 10 g, Mannitol 10 g, Maltitol 19 g, Palatinit 19 g anhydrous)
Number of subjects: 7
Study: 998555

Group type: EXPERIMENTAL
Intervention: Wheat fiber added to metabolically‐controlled diets for 3 weeks
Number of subjects: 6
Study: 31076287

Group type: EXPERIMENTAL
Intervention: Wii Fit balance board exercise program (yoga, strength training, aerobic exercise)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cycle ergometer exercise training
Number of subjects: 0
Study: 28183583

Group type: EXPERIMENTAL
Intervention: Red group (NRS questionnaire printed on red paper)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Green group (NRS questionnaire printed on green paper)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Patients on antidepressants (n=76)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Patients with depression (n=49)
Number of subjects: 200
Study: 26308946

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 70
Study: 23547849

Group type: EXPERIMENTAL
Intervention: Tocilizumab 162 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tocilizumab 162 mg with rHuPH20
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tocilizumab 324 mg with rHuPH20
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tocilizumab 648 mg with rHuPH20
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Increasing doses of tocilizumab
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tocilizumab with and without rHuPH20
Number of subjects: 48
Study: 21714883

Group type: EXPERIMENTAL
Intervention: Care management intervention involving comprehensive assessment of medical and non-medical needs, regular structured monitoring of symptoms, written information, symptom diaries, action plans, and a medication plan for self-management capabilities.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study: 19798550

Group type: EXPERIMENTAL
Intervention: Negative Binomial (NB) model
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Markovian features in lambda and overdispersion parameter
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Zero-Inflated Poisson (ZIP) model
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Zero-Inflated Negative Binomial (ZINB) model
Number of subjects: 551

Group type: COMPARATOR
Intervention: Poisson distribution (PS) model
Number of subjects: 551
Study: 16246976

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy (CRT) with 50.4 Gy and fluorouracil in the first and fifth week
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: TRG 4 (complete response)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Grouped TRG 2 + 3 (intermediate response)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Grouped TRG 0 + 1 (poor response)
Number of subjects: 385
Study: 12390096

Group type: EXPERIMENTAL
Intervention: Tegaserod, 6 mg b.d. (n = 767)
Number of subjects: 1519

Group type: COMPARATOR
Intervention: Placebo (n = 752)
Number of subjects: 1519
Study: 10191213

Group type: EXPERIMENTAL
Intervention: Candidate HIV-1 vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Influenza expansion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tetanus toxoid
Number of subjects: 0
Study: 7762255

Group type: EXPERIMENTAL
Intervention: Megatherapy followed by autologous bone marrow transplantation (MGT/ABMT) in Ewing's sarcoma patients
Number of subjects: 2085

Group type: EXPERIMENTAL
Intervention: Megatherapy followed by autologous bone marrow transplantation (MGT/ABMT) in germ cell tumor patients
Number of subjects: 2085

Group type: EXPERIMENTAL
Intervention: Surgery, megatherapy (BCNU)/ABMT, and radiotherapy in malignant brain gliomas
Number of subjects: 2085
Study: 2263428

Group type: EXPERIMENTAL
Intervention: Regimen A (52 doses)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Regimen B (94 doses)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Both regimens (A and B)
Number of subjects: 76
Study: 7457179

Group type: EXPERIMENTAL
Intervention: Isopaque Cerebral (meglumine‐ca‐metrizoate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amipaque (metrizamide)
Number of subjects: 0
Study: 30109443

Group type: EXPERIMENTAL
Intervention: Clearfil Universal Bond (CU)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: iBOND Universal (IU)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: G‐Premio Bond (GP)
Number of subjects: 18
Study: 28000034

Group type: EXPERIMENTAL
Intervention: Zoledronic acid 4 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Zoledronic acid 5 mg
Number of subjects: 24
Study: 25881458

Group type: EXPERIMENTAL
Intervention: Acupuncture based on infants development theory
Number of subjects: 120

Group type: COMPARATOR
Intervention: Head acupuncture (control group)
Number of subjects: 120
Study: 23605128

Group type: EXPERIMENTAL
Intervention: Electrical Stimulation Therapy (EST) on the suprahyoid muscle only (SM)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Electrical Stimulation Therapy (EST) with one pair of electrodes on the suprahyoid muscle and another pair on the infrahyoid muscle (SI)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Comparison between SM and SI groups
Number of subjects: 50
Study: 21967798

Group type: EXPERIMENTAL
Intervention: C‐TURP+ILC
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: ILC
Number of subjects: 150

Group type: COMPARATOR
Intervention: TURP
Number of subjects: 150